keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LEESGGGLVQPGGSMK, a proteolysis peptide, is a constituent of Infliximab, a chimeric monoclonal IgG1 antibody that selectively binds to TNF-α. It can be employed for quantitative assessment of Infliximab.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
100 mg | Inquiry | Inquiry | |
500 mg | Inquiry | Inquiry |
Description | LEESGGGLVQPGGSMK, a proteolysis peptide, is a constituent of Infliximab, a chimeric monoclonal IgG1 antibody that selectively binds to TNF-α. It can be employed for quantitative assessment of Infliximab. |
In vitro | Anti-TNF antibodies, which block TNF alpha action, have transformed the treatment of TNF-related diseases, including Inflammatory Bowel Disease, lupus, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis. By neutralizing TNF activity, these antibodies not only facilitate mucosal healing but also induce long-term remissions in vivo. The primary anti-TNF antibodies approved for use are Infliximab, Etanercept, Adalimumab, Certolizumab, and Golimumab[1]. |
Molecular Weight | 1545.73 |
Formula | C64H108N18O24S |
CAS No. | 2096980-79-7 |
keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
LEESGGGLVQPGGSMK 2096980-79-7 inhibitor inhibit